Literature DB >> 31502769

HER2 and Breast Cancer - A Phenomenal Success Story.

Daniel F Hayes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31502769     DOI： 10.1056/NEJMcibr1909386

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  32 in total

Review 1.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20

Review 2.  Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.

Authors:  Nischal Koirala; Nandini Dey; Jennifer Aske; Pradip De
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

3.  A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

Authors:  Aleix Prat; Valentina Guarneri; Laia Paré; Gaia Griguolo; Tomás Pascual; Maria V Dieci; Núria Chic; Blanca González-Farré; Antonio Frassoldati; Esther Sanfeliu; Juan M Cejalvo; Montserrat Muñoz; Giancarlo Bisagni; Fara Brasó-Maristany; Loredana Urso; Maria Vidal; Alba A Brandes; Barbara Adamo; Antonino Musolino; Federica Miglietta; Benedetta Conte; Mafalda Oliveira; Cristina Saura; Sònia Pernas; Jesús Alarcón; Antonio Llombart-Cussac; Javier Cortés; Luis Manso; Rafael López; Eva Ciruelos; Francesco Schettini; Patricia Villagrasa; Lisa A Carey; Charles M Perou; Federico Piacentini; Roberto D'Amico; Enrico Tagliafico; Joel S Parker; Pierfranco Conte
Journal:  Lancet Oncol       Date:  2020-11       Impact factor: 41.316

4.  Landscape of combination therapy trials in breast cancer brain metastasis.

Authors:  Jawad Fares; Deepak Kanojia; Aida Rashidi; Ilya Ulasov; Maciej S Lesniak
Journal:  Int J Cancer       Date:  2020-03-09       Impact factor: 7.396

Review 5.  Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2020-03-23

6.  Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.

Authors:  Otto Metzger Filho; Giuseppe Viale; Shayna Stein; Lorenzo Trippa; Denise A Yardley; Ingrid A Mayer; Vandana G Abramson; Carlos L Arteaga; Laura M Spring; Adrienne G Waks; Eileen Wrabel; Michelle K DeMeo; Aditya Bardia; Patrizia Dell'Orto; Leila Russo; Tari A King; Kornelia Polyak; Franziska Michor; Eric P Winer; Ian E Krop
Journal:  Cancer Discov       Date:  2021-05-03       Impact factor: 39.397

7.  Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.

Authors:  Basma M Sharaf; Alexander D Giddey; Hasan Alniss; Hamza M Al-Hroub; Raafat El-Awady; Muath Mousa; Ahmed Almehdi; Nelson C Soares; Mohammad H Semreen
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

8.  Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.

Authors:  Joanne E Mortimer; Laura Kruper; Mary Cianfrocca; Sayeh Lavasani; Sariah Liu; Niki Tank-Patel; Mina Sedrak; Wade Smith; Daphne Stewart; James Waisman; Christina Yeon; Tina Wang; Yuan Yuan
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

9.  Autoantibodies in Early Detection of Breast Cancer.

Authors:  Femina Rauf; Karen S Anderson; Joshua LaBaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-09-29       Impact factor: 4.254

Review 10.  Comprehensive review of targeted therapy for colorectal cancer.

Authors:  Yuan-Hong Xie; Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Signal Transduct Target Ther       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.